• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在慢性丙型肝炎中,采用天然β干扰素诱导法通过抑制丙型肝炎病毒来恢复先天性和适应性免疫反应。

Restoration of innate and adaptive immune responses by HCV viral inhibition with an induction approach using natural interferon-beta in chronic hepatitis C.

作者信息

Kishida Y, Imaizumi N, Tanimura H, Haruna Y, Kashiwamura S, Kashiwagi T

机构信息

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Osaka Kaisei Hospital 1-6-10 Miyahara, Yodogawa-Ku, Osaka City, Osaka 532-0003, Japan.

出版信息

Clin Dev Immunol. 2012;2012:582716. doi: 10.1155/2012/582716. Epub 2012 Aug 27.

DOI:10.1155/2012/582716
PMID:22966239
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3433154/
Abstract

Chronic hepatitis C (CHC) is a serious medical problem necessitating more effective treatment. This study investigated the hypothesis that an induction approach with nIFN-beta for 24 weeks followed by PEG-IFN-alpha+ribavirin (standard of care: SOC) for 48 weeks (novel combination treatment: NCT) would increase the initial virologic response rate and restore innate and adaptive immune responses in CHC. Seven CHC patients with a high viral load and genotype 1b were treated with NCT. Serum cytokine and chemokine levels were evaluated during NCT. NCT prevented viral escape and breakthrough resulting in persistent viral clearance of HCVRNA. IL-15 was increased at the end of induction therapy in both early virologic responders (EAVRs) and late virologic responders (LAVRs); CXCL-8, CXCL-10, and CCL-4 levels were significantly decreased (P < 0.05) in EAVR but not in LAVR during NCT, and IL-12 increased significantly (P < 0.05) and CXCL-8 decreased significantly (P < 0.05) after the end of NCT in EAVR but not in LAVR. NCT prevented viral breakthrough with viral clearance leading to improvement of innate and adaptive immunity resulting in a sustained virologic response (SVR). NCT (n = 8) achieved a higher SVR rate than SOC (n = 8) in difficult-to-treat CHC patients with genotype 1 and high viral loads.

摘要

慢性丙型肝炎(CHC)是一个严重的医学问题,需要更有效的治疗方法。本研究调查了这样一种假设:采用nIFN-β诱导治疗24周,随后使用聚乙二醇干扰素-α+利巴韦林(标准治疗方案:SOC)治疗48周(新型联合治疗方案:NCT),将提高慢性丙型肝炎的初始病毒学应答率,并恢复其固有免疫和适应性免疫应答。7例病毒载量高且基因型为1b的慢性丙型肝炎患者接受了新型联合治疗方案治疗。在新型联合治疗方案治疗期间评估血清细胞因子和趋化因子水平。新型联合治疗方案可防止病毒逃逸和突破,从而实现丙型肝炎病毒核糖核酸(HCVRNA)的持续病毒清除。在早期病毒学应答者(EAVR)和晚期病毒学应答者(LAVR)中,诱导治疗结束时白细胞介素-15(IL-15)均升高;在新型联合治疗方案治疗期间,早期病毒学应答者的CXC趋化因子配体8(CXCL-8)、CXC趋化因子配体10(CXCL-10)和C-C趋化因子配体4(CCL-4)水平显著降低(P<0.05),而晚期病毒学应答者则无此现象;在新型联合治疗方案结束后,早期病毒学应答者的白细胞介素-12显著升高(P<0.05),CXC趋化因子配体8显著降低(P<0.05),晚期病毒学应答者则无此现象。新型联合治疗方案可防止病毒突破并实现病毒清除,从而改善固有免疫和适应性免疫,实现持续病毒学应答(SVR)。在治疗困难的基因型1和病毒载量高的慢性丙型肝炎患者中,新型联合治疗方案(n = 8)的持续病毒学应答率高于标准治疗方案(n = 8)。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/666a/3433154/c0b1f7ccc62a/CDI2012-582716.014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/666a/3433154/fad31e1fa91c/CDI2012-582716.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/666a/3433154/2d9fd5df747c/CDI2012-582716.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/666a/3433154/19ef889f2468/CDI2012-582716.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/666a/3433154/23cb096bd1fa/CDI2012-582716.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/666a/3433154/c0b32bed760b/CDI2012-582716.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/666a/3433154/0d7bd32a8a65/CDI2012-582716.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/666a/3433154/590fb8eb73fc/CDI2012-582716.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/666a/3433154/67a4dae128d2/CDI2012-582716.008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/666a/3433154/3192255ce2f6/CDI2012-582716.009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/666a/3433154/eed7c02a7bc3/CDI2012-582716.010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/666a/3433154/d2571076cb11/CDI2012-582716.011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/666a/3433154/5e2a15a288b4/CDI2012-582716.012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/666a/3433154/b2ac92a8992d/CDI2012-582716.013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/666a/3433154/c0b1f7ccc62a/CDI2012-582716.014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/666a/3433154/fad31e1fa91c/CDI2012-582716.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/666a/3433154/2d9fd5df747c/CDI2012-582716.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/666a/3433154/19ef889f2468/CDI2012-582716.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/666a/3433154/23cb096bd1fa/CDI2012-582716.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/666a/3433154/c0b32bed760b/CDI2012-582716.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/666a/3433154/0d7bd32a8a65/CDI2012-582716.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/666a/3433154/590fb8eb73fc/CDI2012-582716.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/666a/3433154/67a4dae128d2/CDI2012-582716.008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/666a/3433154/3192255ce2f6/CDI2012-582716.009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/666a/3433154/eed7c02a7bc3/CDI2012-582716.010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/666a/3433154/d2571076cb11/CDI2012-582716.011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/666a/3433154/5e2a15a288b4/CDI2012-582716.012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/666a/3433154/b2ac92a8992d/CDI2012-582716.013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/666a/3433154/c0b1f7ccc62a/CDI2012-582716.014.jpg

相似文献

1
Restoration of innate and adaptive immune responses by HCV viral inhibition with an induction approach using natural interferon-beta in chronic hepatitis C.在慢性丙型肝炎中,采用天然β干扰素诱导法通过抑制丙型肝炎病毒来恢复先天性和适应性免疫反应。
Clin Dev Immunol. 2012;2012:582716. doi: 10.1155/2012/582716. Epub 2012 Aug 27.
2
Multiple cytokine profiling of the therapeutic responses to ribavirin and pegylated interferon-alpha2b using an "induction" approach with natural interferon-beta in difficult-to-treat chronic hepatitis C.
J Interferon Cytokine Res. 2009 Jun;29(6):353-68. doi: 10.1089/jir.2008.0110.
3
Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.聚乙二醇干扰素 α-2b/利巴韦林联合治疗时,用干扰素-β/利巴韦林进行导入治疗可能会改变 IL28B 微基因型慢性丙型肝炎患者的早期丙型肝炎病毒动力学。
J Gastroenterol Hepatol. 2013 Mar;28(3):443-9. doi: 10.1111/jgh.12039.
4
[Efficacy and safety of pegylated interferon α-2b injection (Y shape, 40 kD) in treatment of patients with genotype 1/6 chronic hepatitis C].聚乙二醇化干扰素α-2b注射液(Y型,40kD)治疗基因1/6型慢性丙型肝炎患者的疗效与安全性
Zhonghua Gan Zang Bing Za Zhi. 2017 Mar 20;25(3):187-194. doi: 10.3760/cma.j.issn.1007-3418.2017.03.006.
5
Both Hepatitis C Virus-Specific T Cell Responses and IL28B rs12979860 Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C.丙型肝炎病毒特异性T细胞反应和IL28B rs12979860单核苷酸多态性基因型均影响慢性丙型肝炎患者的抗丙型肝炎病毒治疗结果。
J Interferon Cytokine Res. 2017 Jun;37(6):278-286. doi: 10.1089/jir.2016.0078. Epub 2017 Apr 25.
6
HCV-specific CD8+ cell detection at week 12 of chronic hepatitis C treatment with PEG-interferon-α2b/ribavirin correlates with infection resolution.聚乙二醇干扰素α2b/利巴韦林治疗慢性丙型肝炎 12 周时 HCV 特异性 CD8+细胞的检测与感染的清除相关。
Cell Immunol. 2013 Nov-Dec;286(1-2):31-8. doi: 10.1016/j.cellimm.2013.11.001. Epub 2013 Nov 13.
7
Induction pegylated interferon alfa-2b in combination with ribavirin in patients with genotypes 1 and 4 chronic hepatitis C: a prospective, randomized, multicenter, open-label study.聚乙二醇干扰素 α-2b 联合利巴韦林治疗基因型 1 和 4 慢性丙型肝炎患者的前瞻性、随机、多中心、开放性研究。
Clin Gastroenterol Hepatol. 2010 Jan;8(1):66-71.e1. doi: 10.1016/j.cgh.2009.08.036. Epub 2009 Sep 10.
8
[Association between ribavirin plasma concentration and sustained virologic response in treatment of patients with genotype 1b chronic hepatitis C with pegylated interferon-α-2b and ribavirin].聚乙二醇干扰素-α-2b与利巴韦林治疗基因1b型慢性丙型肝炎患者时利巴韦林血浆浓度与持续病毒学应答的相关性
Zhonghua Gan Zang Bing Za Zhi. 2016 Mar 20;24(3):175-80. doi: 10.3760/cma.j.issn.1007-3418.2016.03.004.
9
Prevalence of rs4803217 single nucleotide polymorphism and clinical course of chronic hepatitis C.rs4803217单核苷酸多态性的患病率与慢性丙型肝炎的临床病程
World J Gastroenterol. 2017 Jun 7;23(21):3815-3824. doi: 10.3748/wjg.v23.i21.3815.
10
A Protease Inhibitor with Induction Therapy with Natural Interferon-β in Patients with HCV Genotype 1b Infection.一种蛋白酶抑制剂联合天然干扰素-β诱导疗法用于丙型肝炎病毒1b型感染患者的研究
Int J Mol Sci. 2016 Mar 9;17(3):350. doi: 10.3390/ijms17030350.

引用本文的文献

1
A Protease Inhibitor with Induction Therapy with Natural Interferon-β in Patients with HCV Genotype 1b Infection.一种蛋白酶抑制剂联合天然干扰素-β诱导疗法用于丙型肝炎病毒1b型感染患者的研究
Int J Mol Sci. 2016 Mar 9;17(3):350. doi: 10.3390/ijms17030350.

本文引用的文献

1
Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection.血清 IP-10 水平升高可提高 IL28B 多态性对急性 HCV 感染自发清除的预测价值。
Gastroenterology. 2012 Jan;142(1):78-85.e2. doi: 10.1053/j.gastro.2011.09.039. Epub 2011 Sep 24.
2
Activation of chemokine and inflammatory cytokine response in hepatitis C virus-infected hepatocytes depends on Toll-like receptor 3 sensing of hepatitis C virus double-stranded RNA intermediates.HCV 感染的肝细胞中趋化因子和炎症细胞因子反应的激活依赖于 Toll 样受体 3 对 HCV 双链 RNA 中间体的识别。
Hepatology. 2012 Mar;55(3):666-75. doi: 10.1002/hep.24763. Epub 2012 Jan 30.
3
Both innate and adaptive immunity mediate protective immunity against hepatitis C virus infection in chimpanzees.
先天免疫和适应性免疫共同介导了对感染 HCV 的黑猩猩的保护免疫。
Hepatology. 2011 Oct;54(4):1135-48. doi: 10.1002/hep.24489. Epub 2011 Aug 11.
4
Interferon-β and interferon-λ signaling is not affected by interferon-induced refractoriness to interferon-α in vivo.干扰素-β 和干扰素-λ 信号传导不受体内干扰素诱导的对干扰素-α耐药性的影响。
Hepatology. 2011 Apr;53(4):1154-63. doi: 10.1002/hep.24189.
5
Boceprevir for untreated chronic HCV genotype 1 infection.博赛泼维用于治疗未经治疗的慢性 HCV 基因 1 型感染。
N Engl J Med. 2011 Mar 31;364(13):1195-206. doi: 10.1056/NEJMoa1010494.
6
High-dose pegylated interferon-α and ribavirin in nonresponder hepatitis C patients and relationship with IL-28B genotype (SYREN trial).大剂量聚乙二醇干扰素-α和利巴韦林治疗无应答丙型肝炎患者与 IL-28B 基因型的关系(SYREN 试验)。
Gastroenterology. 2011 Jul;141(1):119-27. doi: 10.1053/j.gastro.2011.03.039. Epub 2011 Mar 24.
7
Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus.直接作用抗病毒药物治疗丙型肝炎病毒的失败和耐药性。
Hepatology. 2011 May;53(5):1742-51. doi: 10.1002/hep.24262.
8
EASL Clinical Practice Guidelines: management of hepatitis C virus infection.欧洲肝脏研究学会临床实践指南:丙型肝炎病毒感染的管理
J Hepatol. 2011 Aug;55(2):245-64. doi: 10.1016/j.jhep.2011.02.023. Epub 2011 Mar 1.
9
Gene regulatory and clinical effects of interferon β in patients with metastatic melanoma: a phase II trial.干扰素 β 在转移性黑色素瘤患者中的基因调控和临床作用:一项 II 期试验。
J Interferon Cytokine Res. 2011 May;31(5):433-40. doi: 10.1089/jir.2010.0054. Epub 2011 Jan 15.
10
Innate or adaptive immunity? The example of natural killer cells.先天免疫还是适应性免疫?以自然杀伤细胞为例。
Science. 2011 Jan 7;331(6013):44-9. doi: 10.1126/science.1198687.